Boston Scientific Corporation Files 10-K/A Amendment
Ticker: BSX · Form: 10-K/A · Filed: Feb 21, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 10-K/A |
| Filed Date | Feb 21, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $54.09 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, Boston Scientific, SEC Filing, Amendment, BSX
TL;DR
<b>Boston Scientific Corporation has filed an amendment to its 2023 10-K report, detailing its corporate structure and listed securities.</b>
AI Summary
BOSTON SCIENTIFIC CORP (BSX) filed a Amended Annual Report (10-K/A) with the SEC on February 21, 2024. Boston Scientific Corporation filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Marlborough, Massachusetts. Boston Scientific Corporation's common stock is traded on the New York Stock Exchange under the ticker symbol BSX. The company also has 0.625% Senior Notes due 2027 listed on the New York Stock Exchange under the symbol BSX27. The filing confirms Boston Scientific Corporation is a well-known seasoned issuer and a large accelerated filer.
Why It Matters
For investors and stakeholders tracking BOSTON SCIENTIFIC CORP, this filing contains several important signals. This amendment provides updated information for the fiscal year ending December 31, 2023, which is crucial for investors to assess the company's current standing and disclosures. The filing confirms the company's status as a well-known seasoned issuer and large accelerated filer, indicating a significant level of public scrutiny and reporting requirements.
Risk Assessment
Risk Level: low — BOSTON SCIENTIFIC CORP shows low risk based on this filing. The filing is an amendment to a 10-K, which is a routine update and does not indicate any new material adverse events.
Analyst Insight
Review the full 10-K/A filing for any specific changes or new disclosures made in this amendment that may impact investment decisions.
Key Numbers
- 2023-12-31 — Fiscal Year End (Fiscal year ended)
- 04-2695240 — IRS Number (IRS Employer Identification No.)
- 0.625% — Senior Notes Interest Rate (0.625% Senior Notes due 2027)
- 2027 — Senior Notes Maturity Year (0.625% Senior Notes due 2027)
Key Players & Entities
- BOSTON SCIENTIFIC CORPORATION (company) — Filer name
- Delaware (jurisdiction) — State of incorporation
- Marlborough, Massachusetts (location) — Address of Principal Executive Offices
- BSX (ticker) — Trading Symbol for Common Stock
- New York Stock Exchange (exchange) — Exchange where Common Stock is registered
- BSX27 (ticker) — Trading Symbol for 0.625% Senior Notes due 2027
FAQ
When did BOSTON SCIENTIFIC CORP file this 10-K/A?
BOSTON SCIENTIFIC CORP filed this Amended Annual Report (10-K/A) with the SEC on February 21, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by BOSTON SCIENTIFIC CORP (BSX).
Where can I read the original 10-K/A filing from BOSTON SCIENTIFIC CORP?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BOSTON SCIENTIFIC CORP.
What are the key takeaways from BOSTON SCIENTIFIC CORP's 10-K/A?
BOSTON SCIENTIFIC CORP filed this 10-K/A on February 21, 2024. Key takeaways: Boston Scientific Corporation filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023.. The company is incorporated in Delaware and its principal executive offices are located in Marlborough, Massachusetts.. Boston Scientific Corporation's common stock is traded on the New York Stock Exchange under the ticker symbol BSX..
Is BOSTON SCIENTIFIC CORP a risky investment based on this filing?
Based on this 10-K/A, BOSTON SCIENTIFIC CORP presents a relatively low-risk profile. The filing is an amendment to a 10-K, which is a routine update and does not indicate any new material adverse events.
What should investors do after reading BOSTON SCIENTIFIC CORP's 10-K/A?
Review the full 10-K/A filing for any specific changes or new disclosures made in this amendment that may impact investment decisions. The overall sentiment from this filing is neutral.
How does BOSTON SCIENTIFIC CORP compare to its industry peers?
Boston Scientific Corporation operates in the medical device industry, specifically in surgical and medical instruments and apparatus.
Are there regulatory concerns for BOSTON SCIENTIFIC CORP?
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.
Industry Context
Boston Scientific Corporation operates in the medical device industry, specifically in surgical and medical instruments and apparatus.
Regulatory Implications
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.
What Investors Should Do
- Review the full 10-K/A filing for any specific changes or new disclosures.
- Verify the details of the listed securities and their associated exchanges.
- Note the company's status as a well-known seasoned issuer and large accelerated filer.
Key Dates
- 2023-12-31: Fiscal Year End — Reporting period for the annual report.
- 2024-02-21: Filing Date — Date the 10-K/A amendment was filed.
Year-Over-Year Comparison
This is an amendment (10-K/A) to the original 10-K filing for the fiscal year ended December 31, 2023.
Filing Stats: 1,118 words · 4 min read · ~4 pages · Grade level 13.1 · Accepted 2024-02-21 16:47:18
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value BSX New York Stock Exchange
- $54.09 — ased on the last reported sale price of $54.09 of the registrant's common stock on the
Filing Documents
- bsx-20231231.htm (10-K/A) — 54KB
- exhibit23-202310xkaeyconse.htm (EX-23) — 4KB
- exhibit311-ceo302202310xka.htm (EX-31.1) — 10KB
- exhibit312-cfo302202310xka.htm (EX-31.2) — 10KB
- 0000885725-24-000020.txt ( ) — 342KB
- bsx-20231231.xsd (EX-101.SCH) — 3KB
- bsx-20231231_def.xml (EX-101.DEF) — 22KB
- bsx-20231231_lab.xml (EX-101.LAB) — 47KB
- bsx-20231231_pre.xml (EX-101.PRE) — 25KB
- bsx-20231231_htm.xml (XML) — 7KB
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)(3) The following documents are filed as a part of this Form 10-K/A: Exhibit No. Title 23 Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP. 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
SIGNATURES
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: February 21, 2024 Boston Scientific Corporation By: /s/ Daniel J. Brennan Daniel J. Brennan Executive Vice President and Chief Financial Officer (duly authorized officer and principal financial officer)